-
Reata CEO on drug that shows signs of reversing kidney damage
Reata CEO Warren Huff discusses his company's new drug, which has shown signs it can reverse kidney damage.
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
#CNBC
published: 02 Apr 2019
-
Why Biogen Agreed to Acquire Reata for $7.3 Billion
Biogen agreed to acquire Reata Pharmaceuticals for $7.3 billion, including debt, to expand its rare disease treatments. Michelle Davis reports on "Bloomberg Markets."
Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.com
Connect with us on...
Twitter: https://twitter.com/business
Facebook: https://www.facebook.com/bloombergbusiness/
Instagram: https://www.instagram.com/quicktake/?hl=en
published: 28 Jul 2023
-
Reata soars on positive drug trial results
CNBC's Meg Tirrell reports on positive drug trial results from Reata Pharmaceuticals that sent shares higher.
published: 15 Oct 2019
-
Biogen to buy rare-disease drugmaker Reata in $7.3B deal
#Biogen #youtube #stockmarket
Yahoo Finance Health Care Reporter Anjalee Khemlani reports on Biogen buying rare-disease drugmaker Reata for $7.3 billion.
Subscribe to Yahoo Finance: https://yhoo.it/2fGu5Bb
About Yahoo Finance:
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Yahoo Finance Plus: With a subscription to Yahoo Finance Plus get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more.
To learn more about Yahoo Finance P...
published: 28 Jul 2023
-
The quality of your clinical data drives everything, says Reata Pharma CEO Warren Huff
Warren Huff, CEO of Reata Pharmaceuticals, and CNBC's Meg Tirrell join 'Power Lunch' to discuss Reata's new drug for treating a rare neurological disorder receiving FDA approval. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Ins...
published: 02 Mar 2023
-
Reata CEO on positive trial results for drug to treat Friedreich's ataxia
Warren Huff, Reata Pharma CEO, joins CNBC's "Power Lunch" team to discuss his company's positive clinical trial results for a drug to treat the neuromuscular disease Friedreich's ataxia.
published: 18 Oct 2019
-
INVESTOR NEWS || Reata Pharmaceuticals is getting bought out by Biogen | What to KNow
Since its founding in 2002, Reata has been leading the dawn of a new era in pharmaceutical approaches for the treatment of serious and life-threatening diseases. We are dedicated to understanding the biology that underlies disease. We strive to understand complex, interconnected molecular pathways with significant potential to impact human pathophysiology, and apply our deep understanding of the cellular response to injury to develop innovative medicines. Our scientific mission is to identify, develop, and commercialize small molecule therapeutics with novel mechanisms of action for the treatment of severe life-threatening diseases that have few or no approved therapies. We focus on molecular pathways that regulate cellular metabolism, inflammation, and the cellular response to injury.
As...
published: 28 Jul 2023
-
Full Interview with Warren Huff, Former CEO of Reata Pharmaceuticals
BioNTX, a leading bioscience and healthcare innovation trade organization and the North Texas life sciences industry applaud the vision and resilience of Reata Pharmaceuticals over their 20-year journey to success. In an exclusive interview with BioNTX, former Reata CEO Warren Huff reflects on the company’s history and commitment to innovating drug development through a combination of disciplined science, skilled talent, and a high-risk, high-reward philosophy.
published: 15 Dec 2023
-
Interview with Warren Huff, Former CEO of Reata Pharmaceuticals
BioNTX, a leading bioscience and healthcare innovation trade organization and the North Texas life sciences industry applaud the vision and resilience of Reata Pharmaceuticals over their 20-year journey to success. In an exclusive interview with BioNTX, former Reata CEO Warren Huff reflects on the company’s history and commitment to innovating drug development through a combination of disciplined science, skilled talent, and a high-risk, high-reward philosophy.
Watch full interview: https://youtu.be/qszxinXVzEA
published: 15 Dec 2023
-
🔴 Reata Pharmaceuticals Inc RETA Stock Information 🔴
Reata Pharmaceuticals Inc RETA Stock Information
__________________________________________________
More Information:
Reata Pharmaceuticals Inc RETA Stock Information
___________________________________________________
Subscribe for More Stock Stuff Here:
https://www.youtube.com/channel/UCeoiYhQ0xv_eXIkOHTop3kg?sub_confirmation=1
__________________________________________________
About this stock:
Reata Pharmaceuticals Inc RETA Stock Information
------------------------------------
Affiliate Disclosure: I may earn a commission for my endorsement, recommendation, testimonial, and/or link to any products or services from the links above. Your purchase helps support my work in bringing you real information about my experience, and does not cost anything additional to you.
DISCLAIMER: Ple...
published: 19 Jul 2022
3:25
Reata CEO on drug that shows signs of reversing kidney damage
Reata CEO Warren Huff discusses his company's new drug, which has shown signs it can reverse kidney damage.
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
...
Reata CEO Warren Huff discusses his company's new drug, which has shown signs it can reverse kidney damage.
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
#CNBC
https://wn.com/Reata_Ceo_On_Drug_That_Shows_Signs_Of_Reversing_Kidney_Damage
Reata CEO Warren Huff discusses his company's new drug, which has shown signs it can reverse kidney damage.
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
#CNBC
- published: 02 Apr 2019
- views: 16490
1:34
Why Biogen Agreed to Acquire Reata for $7.3 Billion
Biogen agreed to acquire Reata Pharmaceuticals for $7.3 billion, including debt, to expand its rare disease treatments. Michelle Davis reports on "Bloomberg Mar...
Biogen agreed to acquire Reata Pharmaceuticals for $7.3 billion, including debt, to expand its rare disease treatments. Michelle Davis reports on "Bloomberg Markets."
Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.com
Connect with us on...
Twitter: https://twitter.com/business
Facebook: https://www.facebook.com/bloombergbusiness/
Instagram: https://www.instagram.com/quicktake/?hl=en
https://wn.com/Why_Biogen_Agreed_To_Acquire_Reata_For_7.3_Billion
Biogen agreed to acquire Reata Pharmaceuticals for $7.3 billion, including debt, to expand its rare disease treatments. Michelle Davis reports on "Bloomberg Markets."
Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.com
Connect with us on...
Twitter: https://twitter.com/business
Facebook: https://www.facebook.com/bloombergbusiness/
Instagram: https://www.instagram.com/quicktake/?hl=en
- published: 28 Jul 2023
- views: 2425
1:44
Reata soars on positive drug trial results
CNBC's Meg Tirrell reports on positive drug trial results from Reata Pharmaceuticals that sent shares higher.
CNBC's Meg Tirrell reports on positive drug trial results from Reata Pharmaceuticals that sent shares higher.
https://wn.com/Reata_Soars_On_Positive_Drug_Trial_Results
CNBC's Meg Tirrell reports on positive drug trial results from Reata Pharmaceuticals that sent shares higher.
- published: 15 Oct 2019
- views: 993
3:23
Biogen to buy rare-disease drugmaker Reata in $7.3B deal
#Biogen #youtube #stockmarket
Yahoo Finance Health Care Reporter Anjalee Khemlani reports on Biogen buying rare-disease drugmaker Reata for $7.3 billion.
Subsc...
#Biogen #youtube #stockmarket
Yahoo Finance Health Care Reporter Anjalee Khemlani reports on Biogen buying rare-disease drugmaker Reata for $7.3 billion.
Subscribe to Yahoo Finance: https://yhoo.it/2fGu5Bb
About Yahoo Finance:
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Yahoo Finance Plus: With a subscription to Yahoo Finance Plus get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more.
To learn more about Yahoo Finance Plus please visit: https://yhoo.it/33jXYBp
Connect with Yahoo Finance:
Get the latest news: https://yhoo.it/2fGu5Bb
Find Yahoo Finance on Facebook: http://bit.ly/2A9u5Zq
Follow Yahoo Finance on Twitter: http://bit.ly/2LMgloP
Follow Yahoo Finance on Instagram: http://bit.ly/2LOpNYz
Follow Yahoo Finance Premium on Twitter: https://bit.ly/3hhcnmV
https://wn.com/Biogen_To_Buy_Rare_Disease_Drugmaker_Reata_In_7.3B_Deal
#Biogen #youtube #stockmarket
Yahoo Finance Health Care Reporter Anjalee Khemlani reports on Biogen buying rare-disease drugmaker Reata for $7.3 billion.
Subscribe to Yahoo Finance: https://yhoo.it/2fGu5Bb
About Yahoo Finance:
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Yahoo Finance Plus: With a subscription to Yahoo Finance Plus get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more.
To learn more about Yahoo Finance Plus please visit: https://yhoo.it/33jXYBp
Connect with Yahoo Finance:
Get the latest news: https://yhoo.it/2fGu5Bb
Find Yahoo Finance on Facebook: http://bit.ly/2A9u5Zq
Follow Yahoo Finance on Twitter: http://bit.ly/2LMgloP
Follow Yahoo Finance on Instagram: http://bit.ly/2LOpNYz
Follow Yahoo Finance Premium on Twitter: https://bit.ly/3hhcnmV
- published: 28 Jul 2023
- views: 1091
6:07
The quality of your clinical data drives everything, says Reata Pharma CEO Warren Huff
Warren Huff, CEO of Reata Pharmaceuticals, and CNBC's Meg Tirrell join 'Power Lunch' to discuss Reata's new drug for treating a rare neurological disorder recei...
Warren Huff, CEO of Reata Pharmaceuticals, and CNBC's Meg Tirrell join 'Power Lunch' to discuss Reata's new drug for treating a rare neurological disorder receiving FDA approval. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
https://www.cnbc.com/select/best-credit-cards/
#CNBC
#CNBCTV
https://wn.com/The_Quality_Of_Your_Clinical_Data_Drives_Everything,_Says_Reata_Pharma_Ceo_Warren_Huff
Warren Huff, CEO of Reata Pharmaceuticals, and CNBC's Meg Tirrell join 'Power Lunch' to discuss Reata's new drug for treating a rare neurological disorder receiving FDA approval. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
https://www.cnbc.com/select/best-credit-cards/
#CNBC
#CNBCTV
- published: 02 Mar 2023
- views: 1278
3:57
Reata CEO on positive trial results for drug to treat Friedreich's ataxia
Warren Huff, Reata Pharma CEO, joins CNBC's "Power Lunch" team to discuss his company's positive clinical trial results for a drug to treat the neuromuscular di...
Warren Huff, Reata Pharma CEO, joins CNBC's "Power Lunch" team to discuss his company's positive clinical trial results for a drug to treat the neuromuscular disease Friedreich's ataxia.
https://wn.com/Reata_Ceo_On_Positive_Trial_Results_For_Drug_To_Treat_Friedreich's_Ataxia
Warren Huff, Reata Pharma CEO, joins CNBC's "Power Lunch" team to discuss his company's positive clinical trial results for a drug to treat the neuromuscular disease Friedreich's ataxia.
- published: 18 Oct 2019
- views: 4986
6:14
INVESTOR NEWS || Reata Pharmaceuticals is getting bought out by Biogen | What to KNow
Since its founding in 2002, Reata has been leading the dawn of a new era in pharmaceutical approaches for the treatment of serious and life-threatening diseases...
Since its founding in 2002, Reata has been leading the dawn of a new era in pharmaceutical approaches for the treatment of serious and life-threatening diseases. We are dedicated to understanding the biology that underlies disease. We strive to understand complex, interconnected molecular pathways with significant potential to impact human pathophysiology, and apply our deep understanding of the cellular response to injury to develop innovative medicines. Our scientific mission is to identify, develop, and commercialize small molecule therapeutics with novel mechanisms of action for the treatment of severe life-threatening diseases that have few or no approved therapies. We focus on molecular pathways that regulate cellular metabolism, inflammation, and the cellular response to injury.
As a purpose-driven company, we believe serving humanity through science has never mattered more. For Biogen, that includes bolstering our commitment to corporate responsibility, caring deeply about making a positive difference for patients, our employees, the environment and the communities where we live and work. Climate, health and equity are deeply interrelated challenges that demand bold action, and that’s why we're advancing a healthier, more sustainable and equitable world.
Discord | https://discord.gg/dXFE9v6p
MooMoo || If you are looking for a platform that allows you to trade premarket and after hours try out MooMoo. Use my link and just deposit $100 and you'll receive 5 free stocks. Want more? Deposit $1000 and you'll get 15 free stocks.
https://j.moomoo.com/00ptPl
We are not financial advisors. The content on this website and our YouTube videos are for educational purposes only and merely cite our own personal opinions. In order to make the best financial decision that suits your own needs, you must conduct your own research and seek the advice of a licensed financial advisor if necessary. Know that all investments involve some form of risk and there is no guarantee that you will be successful in making, saving, or investing money; nor is there any guarantee that you won't experience any loss when investing. Always remember to make smart decisions and do your own research!
#bullish #easymoney #swingtrade #bwb #merger #breakingnews #investornews #parabolic #market #stockmarket #reata #acquistions #reta #retastock #biopharmaceutics #biopharma #biogen #biib #biibstock #arbitrage #allcash #healthcare
https://wn.com/Investor_News_||_Reata_Pharmaceuticals_Is_Getting_Bought_Out_By_Biogen_|_What_To_Know
Since its founding in 2002, Reata has been leading the dawn of a new era in pharmaceutical approaches for the treatment of serious and life-threatening diseases. We are dedicated to understanding the biology that underlies disease. We strive to understand complex, interconnected molecular pathways with significant potential to impact human pathophysiology, and apply our deep understanding of the cellular response to injury to develop innovative medicines. Our scientific mission is to identify, develop, and commercialize small molecule therapeutics with novel mechanisms of action for the treatment of severe life-threatening diseases that have few or no approved therapies. We focus on molecular pathways that regulate cellular metabolism, inflammation, and the cellular response to injury.
As a purpose-driven company, we believe serving humanity through science has never mattered more. For Biogen, that includes bolstering our commitment to corporate responsibility, caring deeply about making a positive difference for patients, our employees, the environment and the communities where we live and work. Climate, health and equity are deeply interrelated challenges that demand bold action, and that’s why we're advancing a healthier, more sustainable and equitable world.
Discord | https://discord.gg/dXFE9v6p
MooMoo || If you are looking for a platform that allows you to trade premarket and after hours try out MooMoo. Use my link and just deposit $100 and you'll receive 5 free stocks. Want more? Deposit $1000 and you'll get 15 free stocks.
https://j.moomoo.com/00ptPl
We are not financial advisors. The content on this website and our YouTube videos are for educational purposes only and merely cite our own personal opinions. In order to make the best financial decision that suits your own needs, you must conduct your own research and seek the advice of a licensed financial advisor if necessary. Know that all investments involve some form of risk and there is no guarantee that you will be successful in making, saving, or investing money; nor is there any guarantee that you won't experience any loss when investing. Always remember to make smart decisions and do your own research!
#bullish #easymoney #swingtrade #bwb #merger #breakingnews #investornews #parabolic #market #stockmarket #reata #acquistions #reta #retastock #biopharmaceutics #biopharma #biogen #biib #biibstock #arbitrage #allcash #healthcare
- published: 28 Jul 2023
- views: 72
36:46
Full Interview with Warren Huff, Former CEO of Reata Pharmaceuticals
BioNTX, a leading bioscience and healthcare innovation trade organization and the North Texas life sciences industry applaud the vision and resilience of Reata ...
BioNTX, a leading bioscience and healthcare innovation trade organization and the North Texas life sciences industry applaud the vision and resilience of Reata Pharmaceuticals over their 20-year journey to success. In an exclusive interview with BioNTX, former Reata CEO Warren Huff reflects on the company’s history and commitment to innovating drug development through a combination of disciplined science, skilled talent, and a high-risk, high-reward philosophy.
https://wn.com/Full_Interview_With_Warren_Huff,_Former_Ceo_Of_Reata_Pharmaceuticals
BioNTX, a leading bioscience and healthcare innovation trade organization and the North Texas life sciences industry applaud the vision and resilience of Reata Pharmaceuticals over their 20-year journey to success. In an exclusive interview with BioNTX, former Reata CEO Warren Huff reflects on the company’s history and commitment to innovating drug development through a combination of disciplined science, skilled talent, and a high-risk, high-reward philosophy.
- published: 15 Dec 2023
- views: 472
3:44
Interview with Warren Huff, Former CEO of Reata Pharmaceuticals
BioNTX, a leading bioscience and healthcare innovation trade organization and the North Texas life sciences industry applaud the vision and resilience of Reata ...
BioNTX, a leading bioscience and healthcare innovation trade organization and the North Texas life sciences industry applaud the vision and resilience of Reata Pharmaceuticals over their 20-year journey to success. In an exclusive interview with BioNTX, former Reata CEO Warren Huff reflects on the company’s history and commitment to innovating drug development through a combination of disciplined science, skilled talent, and a high-risk, high-reward philosophy.
Watch full interview: https://youtu.be/qszxinXVzEA
https://wn.com/Interview_With_Warren_Huff,_Former_Ceo_Of_Reata_Pharmaceuticals
BioNTX, a leading bioscience and healthcare innovation trade organization and the North Texas life sciences industry applaud the vision and resilience of Reata Pharmaceuticals over their 20-year journey to success. In an exclusive interview with BioNTX, former Reata CEO Warren Huff reflects on the company’s history and commitment to innovating drug development through a combination of disciplined science, skilled talent, and a high-risk, high-reward philosophy.
Watch full interview: https://youtu.be/qszxinXVzEA
- published: 15 Dec 2023
- views: 168
0:21
🔴 Reata Pharmaceuticals Inc RETA Stock Information 🔴
Reata Pharmaceuticals Inc RETA Stock Information
__________________________________________________
More Information:
Reata Pharmaceuticals Inc RETA Stock Infor...
Reata Pharmaceuticals Inc RETA Stock Information
__________________________________________________
More Information:
Reata Pharmaceuticals Inc RETA Stock Information
___________________________________________________
Subscribe for More Stock Stuff Here:
https://www.youtube.com/channel/UCeoiYhQ0xv_eXIkOHTop3kg?sub_confirmation=1
__________________________________________________
About this stock:
Reata Pharmaceuticals Inc RETA Stock Information
------------------------------------
Affiliate Disclosure: I may earn a commission for my endorsement, recommendation, testimonial, and/or link to any products or services from the links above. Your purchase helps support my work in bringing you real information about my experience, and does not cost anything additional to you.
DISCLAIMER: Please be advised that I am not a professional advisor in business areas involving finance, cryptocurrency, taxation, securities and commodities trading, or the practice of law. The information and content written, broadcasted, and/or disseminated by and through my channel is intended FOR GENERAL INFORMATION PURPOSES ONLY. Nothing written or discussed is intended to be construed, or relied upon, as investment, financial, legal, regulatory, accounting, tax or similar advice, nor should it be. All content expressed, created, and conveyed by my channel is premised upon subjective opinions pertaining to currently-existing facts readily available.
Webull Referral: https://act.webull.com/on/VgjiEcWqX3l5/ydv/inviteUs/main
Robinhood link: https://join.robinhood.com/anthonc8063
Public.com Referral: https://share.public.com/heyitisanthony
Coinbase Referral: http://coinbase.com/join/chambe_3a?src=ios-link Funded Accounts Up To $300,000 To Day Trade:
https://mailchi.mp/4c26e49ced64/trade-other-peoples-money
https://wn.com/🔴_Reata_Pharmaceuticals_Inc_Reta_Stock_Information_🔴
Reata Pharmaceuticals Inc RETA Stock Information
__________________________________________________
More Information:
Reata Pharmaceuticals Inc RETA Stock Information
___________________________________________________
Subscribe for More Stock Stuff Here:
https://www.youtube.com/channel/UCeoiYhQ0xv_eXIkOHTop3kg?sub_confirmation=1
__________________________________________________
About this stock:
Reata Pharmaceuticals Inc RETA Stock Information
------------------------------------
Affiliate Disclosure: I may earn a commission for my endorsement, recommendation, testimonial, and/or link to any products or services from the links above. Your purchase helps support my work in bringing you real information about my experience, and does not cost anything additional to you.
DISCLAIMER: Please be advised that I am not a professional advisor in business areas involving finance, cryptocurrency, taxation, securities and commodities trading, or the practice of law. The information and content written, broadcasted, and/or disseminated by and through my channel is intended FOR GENERAL INFORMATION PURPOSES ONLY. Nothing written or discussed is intended to be construed, or relied upon, as investment, financial, legal, regulatory, accounting, tax or similar advice, nor should it be. All content expressed, created, and conveyed by my channel is premised upon subjective opinions pertaining to currently-existing facts readily available.
Webull Referral: https://act.webull.com/on/VgjiEcWqX3l5/ydv/inviteUs/main
Robinhood link: https://join.robinhood.com/anthonc8063
Public.com Referral: https://share.public.com/heyitisanthony
Coinbase Referral: http://coinbase.com/join/chambe_3a?src=ios-link Funded Accounts Up To $300,000 To Day Trade:
https://mailchi.mp/4c26e49ced64/trade-other-peoples-money
- published: 19 Jul 2022
- views: 93